Will Garner
Impact in
- Virology top 5%
- HIV Research and Treatment
- Infectious Diseases top 5%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
Papers in
-
- HIV/AIDS drug development and treatment 13
- Surgery 8
- Pediatric Hepatobiliary Diseases and Treatments 7
- Co-authors
- Anton Pozniak (4 shared papers)Kirsten White (5 shared papers)Erin Quirk (3 shared papers)Andrew Cheng (2 shared papers)Andrea Antinori (4 shared papers)Hans-Jürgen Stellbrink (2 shared papers)Joseph M. Custodio (1 shared paper)Edwin DeJesus (1 shared paper)
- Journals
- Patient (3 papers)AIDS (3 papers)Journal of Hepatology (3 papers)Journal of the International AIDS Society (3 papers)The Lancet (2 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Will Garner
26 papers receiving 777 citations
Will Garner's Hit Papers
Peers
Comparison fields: 5 of 45
- Virology 193
- Infectious Diseases 456
- Emergency Medicine 128
- Hepatology 107
- Oncology 100
Countries citing papers authored by Will Garner
This map shows the geographic impact of Will Garner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Will Garner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Will Garner more than expected).
Fields of papers citing papers by Will Garner
This network shows the impact of papers produced by Will Garner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Will Garner. The network helps show where Will Garner may publish in the future.
Co-authors
The 25 scholars most cited alongside Will Garner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial Hit paper breakdown → | 2017 | 292 |
| 2 | 2021 | 105 | |
| 3 | 2014 | 75 | |
| 4 | 2016 | 47 | |
| 5 | 2013 | 47 | |
| 6 | 2022 | 43 | |
| 7 | 2018 | 43 | |
| 8 | 2015 | 32 | |
| 9 | 2015 | 17 | |
| 10 | 2022 | 15 | |
| 11 | 2015 | 11 | |
| 12 | 2015 | 11 | |
| 13 | 2023 | 8 | |
| 14 | 2014 | 6 | |
| 15 | 2014 | 6 | |
| 16 | 2019 | 6 | |
| 17 | 1974 | 6 | |
| 18 | 2016 | 3 | |
| 19 | 2014 | 3 | |
| 20 | 2023 | 3 |
About Will Garner
Will Garner is a scholar working on Infectious Diseases, Surgery, Oncology, Hepatology and Epidemiology, having authored 29 papers that have together received 786 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (13 papers), Pediatric Hepatobiliary Diseases and Treatments (7 papers), Liver Diseases and Immunity (4 papers), Drug Transport and Resistance Mechanisms (3 papers), HIV Research and Treatment (2 papers), Pneumocystis jirovecii pneumonia detection and treatment (1 paper), Acute Lymphoblastic Leukemia research (1 paper) and Gallbladder and Bile Duct Disorders (1 paper). The work is most often cited by research in Virology (193 citations), Infectious Diseases (456 citations), Emergency Medicine (128 citations), Hepatology (107 citations) and Oncology (100 citations). Will Garner has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Anton Pozniak, Kirsten White, Erin Quirk, Andrew Cheng, Andrea Antinori, Hans-Jürgen Stellbrink, Joseph M. Custodio, Edwin DeJesus, Jacques Reynes and Paul E. Sax. Their work appears in journals such as Patient, AIDS, Journal of Hepatology, Journal of the International AIDS Society and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.